Peginterferon_alfa-2b: profile and news

MIGENIX Receives Approval for MX-3253 Phase II Combination Viral ... 16 May 2006
The study is designed to demonstrate improved antiviral activity when celgosivir is used in combination with peginterferon alfa-2b, with or without ribavirin ... - Yahoo! News (press release)

EU Label Change for Intron A (Interferon Alfa-2b) Incorporates ... Apr 26, 2006
Schering-Plough also markets a longer-acting, once-weekly pegylated version of interferon alfa-2b called PEG-Intron (peginterferon alfa-2b), for use as ... - DG News

EU Label Change for INTRON(R) A (interferon alfa-2b) Incorporates ... Apr 25, 2006
Schering-Plough also markets a longer-acting, once-weekly pegylated version of interferon alfa-2b called PEGINTRON (peginterferon alfa-2b), for use as ... - Finanzen.net,

MIGENIX to Present at Several Upcoming Investor and Scientific ... May 2, 2006
I inhibitor for the treatment of chronic hepatitis C virus (HCV) infections currently enrolling patients in combination with peginterferon alfa-2b; with and ... - Yahoo! News (press release)

WIN-R Study Demonstrates Efficacy of Shorter PEG-Intron and ... Apr 28, 2006
...patients infected with hepatitis C virus (HCV) genotype 2 or 3, a shorter, 24-week course of therapy with PEG-Intron(R) (peginterferon alfa-2b) in combination ... - DG News

Schering-Plough's shorter dose hepatitis regimen shows promise May 2, 2006
..."These findings are important because they confirm the effectiveness of a shorter course of peginterferon alfa-2b and ribavirin combination therapy for ... - Pharmaceutical Business Review

Schering-Plough Advances Development of Hepatitis Capsules Apr 21, 2006
SCH 503034 is being evaluated in a large phase II study in combination with peg-intron (peginterferon alfa-2b) for the treatment of patients chronically ... - International News Service,

Schering-Plough Provides Update on Oral HCV Protease Inhibitor SCH ... Apr 19, 2006
SCH 503034 is being evaluated in a large Phase II study in combination with PEG-INTRON® (peginterferon alfa-2b) for the treatment of patients chronically ... - Yahoo! News (press release)

Schering-Plough Provides Phase II Hepatitis C Drug Update Apr 20, 2006
SCH 503034 is being evaluated in a Phase II study in combination with PEG-INTRON, or peginterferon alfa-2b, for the treatment of patients chronically infected ... - Therapeutics Daily (subscription) (press release),

Other information

Indication
For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma

Pharmacology
Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.

Mechanism Of Action
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.

Drug Category
Antiviral Agents; Immunomodulatory Agents; Antineoplastic Agents; interferons (08:18.20)

Brand Names/Synonyms
Interferon alpha-2 precursor;Interferon alpha-A;LeIF A; PEG-Intron

Dosage Forms
POWDER FOR SOLUTION

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
PEGylated human interferon alpha 2b

Chemical Formula
C860H1353N229O255S9

Half Life
22-60 hrs

Drug Type
Approved Drug

# Accession No
BIOD00048

CAS Registry Number
99210-65-8